Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PLD1 | Q13393 | 5/20 | 0.38 |
| ▸ | PLD2 | O14939 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12492338 | 0.75 | MEN1 (0.43) | KMT2A | |
| SCHEMBL12410059 | 0.75 | KMT2A (0.45) | SLC6A9OPRM1SLC6A5KCNH2KMT2A | |
| SCHEMBL8212205 | 0.72 | CACNA1H (0.58) | KMT2A | |
| SCHEMBL15099412 | 0.68 | AGTR2 (0.47) | SLC6A9OPRM1SLC6A5KCNH2KMT2A | |
| SCHEMBL14058007 | 0.67 | RORC (0.41) | KMT2A | |
| SCHEMBL7354999 | 0.66 | KMT2A (0.51) | KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL15094369 | 0.66 | AGTR2 (0.51) | SLC6A9OPRM1SLC6A5KCNH2KMT2A | |
| SCHEMBL16367030 | 0.65 | AGTR2 (0.47) | SLC6A9OPRM1SLC6A5KCNH2KMT2A | |
| SCHEMBL14263456 | 0.65 | AGTR2 (0.39) | SLC6A9OPRM1KMT2A | |
| SCHEMBL14263430 | 0.64 | AGTR2 (0.49) | SLC6A9OPRM1SLC6A5KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | SLC6A9 3513/4885OPRM1 1209/4885SLC6A5 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.